W
William G. Wierda
Researcher at University of Texas MD Anderson Cancer Center
Publications - 943
Citations - 49801
William G. Wierda is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 101, co-authored 842 publications receiving 42404 citations.
Papers
More filters
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Richard R. Furman,Steven Coutre,Ian W. Flinn,Jan A. Burger,Kristie A. Blum,Barbara Grant,Jeff P. Sharman,Morton Coleman,William G. Wierda,Jeffrey A. Jones,Weiqiang Zhao,Nyla A. Heerema,Amy J. Johnson,Juthamas Sukbuntherng,Betty Y. Chang,Fong Clow,Eric Hedrick,Joseph J. Buggy,Danelle F. James,Susan O'Brien +20 more
TL;DR: Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.
Journal ArticleDOI
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
Sattva S. Neelapu,Sudhakar Tummala,Partow Kebriaei,William G. Wierda,Cristina Gutierrez,Frederick L. Locke,Krishna V. Komanduri,Yi Lin,Nitin Jain,Naval Daver,Jason R. Westin,Alison M. Gulbis,Monica Loghin,John de Groot,Sherry Adkins,Suzanne E. Davis,Katayoun Rezvani,Patrick Hwu,Elizabeth J. Shpall +18 more
TL;DR: The multidisciplinary approach adopted at institutions is described, and recommendations for monitoring, grading, and managing the acute toxicities that can occur in patients treated with CAR-T-cell therapy are provided.
Journal ArticleDOI
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts,Matthew S. Davids,John M. Pagel,Brad S. Kahl,Soham D. Puvvada,John F. Gerecitano,Thomas J. Kipps,Mary Ann Anderson,Mary Ann Anderson,Jennifer R. Brown,Lori A. Gressick,Shekman Wong,Martin Dunbar,Ming Zhu,Monali Desai,Elisa Cerri,Sari H. Enschede,Rod A. Humerickhouse,William G. Wierda,John F. Seymour,John F. Seymour +20 more
TL;DR: Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features.
Journal ArticleDOI
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu,David Marin,Pinaki P. Banerjee,Homer A. Macapinlac,Philip A. Thompson,Rafet Basar,Lucila Nassif Kerbauy,Bethany J Overman,Peter F. Thall,Mecit Kaplan,Vandana Nandivada,Indresh Kaur,Ana Karen Nunez Cortes,Kai Cao,May Daher,Chitra Hosing,Evan N. Cohen,Partow Kebriaei,Rohtesh S. Mehta,Sattva S. Neelapu,Yago Nieto,Michael Wang,William G. Wierda,Michael J. Keating,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani +26 more
TL;DR: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects.
Journal ArticleDOI
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
Michael J. Keating,Susan O'Brien,Maher Albitar,Susan Lerner,William Plunkett,Francis J. Giles,Michael Andreeff,Jorge E. Cortes,Stefan Faderl,Deborah A. Thomas,Charles Koller,William G. Wierda,Michelle A. Detry,Alice Lynn,Hagop M. Kantarjian +14 more
TL;DR: FCR produced a high CR rate in previously untreated CLL, and most patients had no detectable disease on flow cytometry at the end of therapy.